Eli Lilly and Indiana University have entered a $40 million agreement to enhance access to clinical trials in Indiana, focusing on Alzheimer’s disease, diabetes, cancer, and cell and gene therapy.

The partnership aims to accelerate research, improve patient care, and develop talent in the life sciences sector.

IU LAB will lead the collaboration, with plans to expand the partnership based on successful outcomes.